XENETIC BIOSCIENCES, INC. Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31)
XENETIC BIOSCIENCES, INC. (XBIO) reported Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) of 0.52% for the 9-month period ending 2016-09-30, per its 10-Q filed 2017-11-14.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsRiskFreeInterestRate · last filed 2017-11-14
- 2016-09-30: Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 9 month 0.52%.
| Period end | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 9 month |
|---|---|
| 2016-09-30 | 0.52% 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |